Showing 1771-1780 of 5957 results for "".
- Appeals Court Rules HHS Has Authority to Implement Site Neutral Payments, Dealing Blow to Hospitalshttps://modernod.com/news/appeals-court-rules-hhs-has-authority-to-implement-site-neutral-payments-dealing-blow-to-hospitals/2478041/A federal appeals court ruled Health and Human Services has the authority to cut Medicare payments to off-campus clinics to bring them in line with independent physician practices, reversing a lower court’s decision, according to a FierceHealthcare
- Johnson & Johnson Takes Charge of Emergent COVID-19 Vaccine Manufacturing Sitehttps://modernod.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/The US Department of Health & Human Services (HHS) has put Johnson & Johnson in charge of the Emergent BioSolutions’ Bayview facility in Baltimore, which ruined around 15 million doses of its COVID-19 vaccine Ad26.COV2.S. Johnson & Johnson said it was “assuming full
- Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Activehttps://modernod.com/news/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/2481699/Dopavision announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.
- Google Commits $150M to COVID-19 Vaccine Education, Partnering With One Medical to Open Vaccination Siteshttps://modernod.com/news/google-commits-150m-to-covid-19-vaccine-education-partnering-with-one-medical-to-open-vaccination-sites/2478801/Google is committing $150 million to promote COVID-19 vaccine education and equitable distribution to underserved communities, the tech giant announced Monday, as
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bankhttps://modernod.com/news/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank/2479182/Eyenovia announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). “This non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we
- New Collaboration to Produce Opticianry-Focused Educational Panel at OptiCon ’26https://modernod.com/news/new-collaboration-to-produce-opticianry-focused-educational-panel-at-opticon-26/2485385/The Contact Lens Institute (CLI) and the United Opticians Association (UOA) announced a new collaboration to co-produce "Vision for Growth: Consumer Perspectives on Opticianry & Contact Lens Success," an educational panel exclusive to OptiCon ’26 @ Vision Expo.
- US States Sue 26 Generic Drugmakers for Alleged Price Fixinghttps://modernod.com/news/us-states-sue-26-generic-drugmakers-for-alleged-price-fixing/2479522/A coalition of 51 US states and territories filed a lawsuit in federal court in Connecticut on Wednesday, accusing 26 drug companies, including Taro, Perrigo, Novartis’ Sandoz unit, Actavis, Mylan, Teva, G&W and Glenmark, of conspiring to fix prices and allocate markets for at least 80
- Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technologyhttps://modernod.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/Eyenuk announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million. The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS,
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)